Targeting glial metabolism in neurodegenerative diseases: detail matters

Neurodegenerative diseases, a group of disorders associated with advanced age, are typified by the disease-specific accumulation of mutant proteins and neuroinflammation. For decades, treatment modalities for these disorders have focused on addressing neuronal malfunction, which has resulted in the failure of therapies. Recent studies have identified the crucial role of glial cells in exacerbating neurodegenerative processes via the release of neuroinflammatory mediators. Glia, the major immune component of the central nervous system (CNS), undergo numerous phenotypic transitions and regulate the outcomes of various pathologies (Afridi et al., 2022).